Literature DB >> 22358413

[Capability of national reference laboratories in Latin America to detect emerging resistance mechanisms].

Alejandra Corso1, Leonor Guerriero, Fernando Pasterán, Paola Ceriana, Raquel Callejo, Mónica Prieto, Ezequiel Tuduri, Horacio Lopardo, Carlos Vay, Jorgelina Smayevsky, Marta Tokumoto, Jorge Matheu Alvarez, Pilar Ramón Pardo, Marcelo Galas.   

Abstract

OBJECTIVE: To evaluate the capability of 17 national reference laboratories participating in the Latin American Quality Control Program in Bacteriology and Antibiotic Resistance (LA-EQAS) to detect emerging resistance mechanisms- namely: resistance of enterobacteria to carbapenems due to the presence of Klebsiella pneumoniae carbapenemase (KPC) and metallo-beta-lactamase (MBL) type IMP, and intermediate resistance of Staphylococcus aureus isolates to vancomycin (vancomycin-intermediate resistant S. aureus-VISA).
METHODS: The following three isolates were sent to the 17 participating LA-EQAS laboratories: KPC -producing Klebsiella pneumoniae PAHO-161, IMP-producing Enterobacter cloacae PAHO-166, and S. aureus PAHO-165 with intermediate resistance to vancomycin. Performance of each of the following operations was evaluated: interpretation of sensitivity tests, detection of the resistance mechanism, and assessment of either inhibition halo size (disk diffusion method) or minimum inhibitory concentration (MIC).
RESULTS: Concordance in the detection of resistance mechanisms was 76.4%, 73.3%, and 66.7% for the K. pneumoniae PAHO-161, E. cloacae PAHO-166, and S. aureus PAHO-165 strains, respectively. Concordance between the inhibition areas observed by the participating laboratories and the ranges established by the coordinating laboratory was acceptable for all three isolates, at 90.8%, 92.8%, and 88.9%, respectively.
CONCLUSIONS: Overall concordance in on the detection of KPC, MBL, and VISA resistance mechanisms was 72.1%. We consider the national reference laboratories in Latin America capable of recognizing these emerging resistance mechanisms and expect that maximum levels of concordance will be reached in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22358413     DOI: 10.1590/s1020-49892011001200021

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  3 in total

1.  [Evolution of the performance of Latin America Reference Laboratories in the detection of mechanisms of antimicrobial resistanceEvolução do desempenho dos Laboratórios de Referência na América Latina na detecção de mecanismos de resistência antimicrobiana].

Authors:  Paula Gagetti; Fernando Pasteran; Paola Ceriana; Mónica Prieto; Lucía Cipolla; Ezequiel Tuduri; Nienke Bruinsma; Marcelo Galas; Pilar Ramón-Pardo; A Corso
Journal:  Rev Panam Salud Publica       Date:  2020-09-23

2.  Estrategia de control de la resistencia bacteriana a los antimicrobianos en Argentina.

Authors:  Jaime Lazovski; Alejandra Corso; Fernando Pasteran; Mauricio Monsalvo; Julia Frenkel; Wanda Cornistein; Gonzalo Corral; Francisco Nacinovich
Journal:  Rev Panam Salud Publica       Date:  2017-06-19

3.  Disparities in antimicrobial consumption and resistance within a country: the case of beta-lactams in Argentina.

Authors:  Silvia Boni; Gustavo H Marin; Laura Campaña; Lupe Marin; Alejandra Corso; Soledad Risso-Patron; Fernanda Gabriel; Valeria Garay; Manuel Limeres
Journal:  Rev Panam Salud Publica       Date:  2021-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.